Literature DB >> 16594932

Metronidazole with Lactacyd vaginal gel in bacterial vaginosis.

Ditas Cristina D Decena1, Jennifer T Co, Ricardo M Manalastas, Evelyn P Palaypayon, Christia S Padolina, Judith M Sison, Louella A Dancel, Marievi A Lelis.   

Abstract

AIM: To assess the efficacy and tolerability of lactic acid (Lactacyd vaginal gel; LVG) when given as an adjunct to metronidazole in the treatment of bacterial vaginosis (BV) among Filipino patients.
METHODS: A multicenter, open-labeled, controlled, randomized, three-arm comparative study on 90 women aged 18 years or over with clinically and microbiologically proven BV.
RESULTS: The lactobacilli colony count significantly increased over time in all three arms. At day 14, growth of lactobacilli was significantly higher among patients in the lactic acid gel and combination treatment arms. Significant reduction of malodorous vaginal discharge (whiff test) and lowest recurrence of BV were noted in the metronidazole plus lactic acid gel arm. Regarding disappearance of signs of BV, there was significant decrease in the pH level and frequency of clue cell positive patients across time but was not significantly different across treatment groups. Only one patient (3%, 1/60) among those who received lactic acid gel complained of increased curd-like discharge. Six patients (10%, 6/60) who received metronidazole complained of epigastric pain/discomfort, dizziness and dyspnea.
CONCLUSIONS: Lactic acid gel (LVG) is safe and as efficacious as metronidazole in the treatment of BV. There is evidence that LVG when combined with metronidazole is superior to metronidazole alone in promoting lactobacilli colonization. LVG as an adjunct to metronidazole, having the least number of recurrent BV, appears to result in better long-term treatment effect on bacterial vaginosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16594932     DOI: 10.1111/j.1447-0756.2006.00383.x

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  10 in total

1.  NATURAL ANTIMICROBIALS AND THEIR ROLE IN VAGINAL HEALTH: A SHORT REVIEW.

Authors:  S E Dover; A A Aroutcheva; S Faro; M L Chikindas
Journal:  Int J Probiotics Prebiotics       Date:  2008

2.  Non-antibiotic treatment of bacterial vaginosis-a systematic review.

Authors:  Fiona Damaris Tidbury; Anita Langhart; Susanna Weidlinger; Petra Stute
Journal:  Arch Gynecol Obstet       Date:  2020-10-06       Impact factor: 2.344

3.  Vaginal treatment with lactic acid gel delays relapses in recurrent urinary tract infections: results from an open, multicentre observational study.

Authors:  Ruth Diebold; Bettina Schopf; Holger Stammer; Werner Mendling
Journal:  Arch Gynecol Obstet       Date:  2021-03-27       Impact factor: 2.344

4.  Antibacterial treatment of bacterial vaginosis: current and emerging therapies.

Authors:  Jean-Pierre Menard
Journal:  Int J Womens Health       Date:  2011-08-23

5.  Bacterial vaginosis: Etiology and modalities of treatment-A brief note.

Authors:  Nikhil Kumar; Beauty Behera; Sai S Sagiri; Kunal Pal; Sirsendu S Ray; Saroj Roy
Journal:  J Pharm Bioallied Sci       Date:  2011-10

6.  Vaginal concentrations of lactic acid potently inactivate HIV.

Authors:  Muriel Aldunate; David Tyssen; Adam Johnson; Tasnim Zakir; Secondo Sonza; Thomas Moench; Richard Cone; Gilda Tachedjian
Journal:  J Antimicrob Chemother       Date:  2013-05-08       Impact factor: 5.790

7.  Vaginal Lactobacillus Inhibits HIV-1 Replication in Human Tissues Ex Vivo.

Authors:  Rogers A Ñahui Palomino; Sonia Zicari; Christophe Vanpouille; Beatrice Vitali; Leonid Margolis
Journal:  Front Microbiol       Date:  2017-05-19       Impact factor: 5.640

8.  Effects of an over-the-counter lactic-acid containing intra-vaginal douching product on the vaginal microbiota.

Authors:  C van der Veer; S M Bruisten; R van Houdt; A A Matser; G Tachedjian; J H H M van de Wijgert; H J C de Vries; J J van der Helm
Journal:  BMC Microbiol       Date:  2019-07-25       Impact factor: 3.605

9.  Metronidazole versus lactic acid for treating bacterial vaginosis (VITA): protocol for a randomised controlled trial to assess the clinical and cost effectiveness of topical lactic acid gel for treating second and subsequent episodes of bacterial vaginosis.

Authors:  Lindsay Armstrong-Buisseret; Clare Brittain; Miruna David; Gillian Dean; Frances Griffiths; Trish Hepburn; Louise Jackson; Joe Kai; Alan Montgomery; Tracy Roberts; Sukhwinder Thandi; Jonathan D C Ross
Journal:  Trials       Date:  2019-11-27       Impact factor: 2.279

10.  Rationale and Safety Assessment of a Novel Intravaginal Drug-Delivery System with Sustained DL-Lactic Acid Release, Intended for Long-Term Protection of the Vaginal Microbiome.

Authors:  Hans Verstraelen; Chris Vervaet; Jean-Paul Remon
Journal:  PLoS One       Date:  2016-04-19       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.